Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (note: metadata lists "Alterity Therapeutics Ltd," but the filing text identifies the registrant as Prana Biotechnology Limited) covers the month of December 2006. The document serves as a New Issue Announcement and application for quotation of additional securities with the Australian Securities Exchange (ASX). The company is headquartered in South Melbourne, Victoria, Australia.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes.
- Ordinary Shares Issued: 15,000 shares issued at $0.00 consideration.
- Unlisted Options Issued: 312,500 options (exercisable at $0.00 if share price reaches $0.40 for 5 consecutive days by August 7, 2014) and 3,200,000 options (exercisable at $0.00 if share price reaches $0.80 for 5 consecutive days by July 31, 2009).
- Total Quoted Ordinary Shares: 144,105,506.
- Existing Unquoted Securities: Includes various unlisted options and warrants with exercise prices ranging from nil to US$8.00 and expiry dates between 2007 and 2014.
Material Changes
The primary material change is the issuance of new securities under the Employee Incentive Scheme 2004 and resolutions from the 2006 Annual General Meeting. These securities were entered into uncertificated holdings on December 1, 2006. The new ordinary shares rank pari passu with existing shares, while the new options rank equally upon exercise.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It does not disclose specific risks or contingencies beyond standard regulatory warranties regarding the legality of the issue and compliance with the Corporations Act. The dividend policy remains unchanged.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Alterity Therapeutics Ltd") and the filing registrant ("Prana Biotechnology Limited").
- Confirm the dilution impact of the 3,512,500 new unlisted options issued at nil consideration.
- Review the specific conditions for option exercise (share price thresholds of $0.40 and $0.80) to assess potential future dilution.
- Check the total number of outstanding unlisted options and warrants listed in Clause 9 to understand the full potential share count.